Gene therapy successful in treating leukemia. Can it be used to fight other cancers as well?

targeted cellular therapy cancer penn banner
Image via Singularity Hub.

A new cancer treatment pioneered at the University of Pennsylvania has generated excitement in the field in addition to a handful of breathless media reports. Called targeted cellular therapy, the approach has given several dozen patients what Laurence Cooper of the MD Anderson Cancer Center called “a Lazarus moment.”

The patients all suffered from lymphocytic leukemia and had exhausted other treatment options. The researchers, Carl June and David Porter, announced the results recently at the American Society of Hematology Annual Meeting and Exposition in New Orleans.

“Those patients were facing certain death,” said Cooper, who wasn’t involved in the Penn study but is researching a similar treatment at MD Anderson.

After receiving targeted cellular therapy, 26 of 59 patients, including 19 children, are now cancer-free. Patients with the acute form of the cancer, which affects both children and adults, were especially likely to respond positively to treatment.

Targeted cellular therapy is an extension of long-standing efforts to ramp up the patient’s own immune system to destroy cancer cells. With advances in genetics, doctors can now reconfigure patients’ T cells to target a particular type of cancer cell.

The treatment isn’t without risk, though. Although none have died from the treatment, patients suffer severe flu-like symptoms while the revved-up immune cells do their work. They require round-the-clock medical care, sometimes including the immunosuppressant drug tocilizumab.

Given the promising results for leukemia patients, researchers are already pursuing similar approaches for pancreatic and breast cancers as well as glioma, the type of brain cancer that killed Ted Kennedy.

Read the full, original article: Gene Therapy Turns Several Leukemia Patients Cancer Free. Will it Work For Other Cancers, Too?

Additional Resources: 

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

Screenshot-2026-03-13-at-12.14.04-PM
The FDA wants to make many popular prescription drugs OTC—a great idea. Here’s why it’s unlikely to happen
Screenshot-2026-05-04-at-12.54.32-PM
How Utah became the country’s supplement capital  — and a haven for unregulated, ineffective and fake products
Screenshot-2026-04-20-at-2.26.27-PM
Viewpoint — Food-fear world: The latest activist scientists campaign: Cancer-causing additives
Screenshot-PM-24
Viewpoint: The herbicide glyphosate isn’t perfect. Banning it would be far worse.
images
The never-ending GMO debate: Pros and cons
Screenshot-2026-05-01-at-11.56.24-AM
‘Science moves forward when people are willing to think differently’: Memories of DNA maverick Craig Venter
Screenshot-2026-04-30-at-2.19.37-PM
5 myths about summer dehydration that could damage your health — or even kill you
Screenshot-2026-04-03-at-11.15.51-AM
Paraben panic: How a flawed study, media hype, and chemophobia convinced the public of the danger of one of the safest classes of preservatives
79d03212-2508-45d0-b427-8e9743ff6432
Viewpoint: The Casey Means hustle—Wellness woo opportunism dressed up as medical wisdom
bigstock opioids on chalkboard with rol
GLP podcast: 'Safe injection sites': enabling drug addiction or saving lives?
ChatGPT-Image-May-1-2026-02_20_13-PM
How RFK, Jr.’s false vaccine claims are holding up $600 million to fight diseases in poor countries
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.